Epratuzumab (anti-CD22 mAb targeting b-cells) provides clinically meaningful reductions in corticosteroid (CS) use with a favorable safety profile in patients with Moderate/Severe flaring SLE: Results from Randomized controlled trials (RCTs)
Year: 2008
Type: article
Source: Arthritis & Rheumatism
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2245603003
